Clinical Trials Logo

Urinary Tract Infections clinical trials

View clinical trials related to Urinary Tract Infections.

Filter by:

NCT ID: NCT00734968 Completed - Clinical trials for Post-Operative Urinary Tract Infection in Patients Undergoing Placement of a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence

Does Post-Operative Prophylaxis With Macrobid Reduce the Incidence of Post-Operative Urinary Tract Infection in Patients Undergoing Placement of a Sub-Urethral Sling for the Treatment of Stress Urinary Incontinence

Start date: May 2008
Phase: Phase 4
Study type: Interventional

This project will be a randomized, double blinded, placebo controlled clinical trial. The aim of the trial is to determine whether or not post-operative prophylaxis with macrobid will decrease the incidence of postoperative urinary tract infection in women receiving sub-urethral slings for the treatment of urinary incontinence.

NCT ID: NCT00732238 Completed - Spinal Cord Injury Clinical Trials

Multifaceted Treatment of Catheter-related Urinary Tract Infection

Start date: July 2007
Phase: Phase 2
Study type: Interventional

The specific objective of this clinical trial is to demonstrate that a multifaceted approach for treatment for catheter-related urinary tract infection (UTI) in patients with spinal cord injury is effective and feasible. We plan to test the following hypothesis: a multifaceted treatment approach that consists of immediate removal of the indwelling bladder catheter, selecting antibiotics based on the finding from a urine culture that is obtained through the newly inserted catheter, and a 5-day course of systemic antibiotics will effectively treat catheter-related infection that is limited to the lower urinary tract of patients with spinal cord injury.

NCT ID: NCT00722735 Completed - Clinical trials for Urinary Tract Infections

Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)

FLUT
Start date: October 2008
Phase: Phase 2
Study type: Interventional

To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI.

NCT ID: NCT00714792 Completed - Overactive Bladder Clinical Trials

Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?

Start date: June 2008
Phase: N/A
Study type: Observational

The purpose of this study is to look for evidence of bacteria in the urine or bladder of people with overactive bladder. Because you do not have overactive bladder, your participation in this study will be used as a comparison to those who have overactive bladder.

NCT ID: NCT00714402 Completed - Clinical trials for Bacterial Infections

Procalcitonin Level and Kinetics in Children With Bacterial Infections

Start date: August 2008
Phase: N/A
Study type: Observational

The purposes of this study are: 1. To determine whether procalcitonin level at admission of pediatric patients with bacterial infections can be used as a marker for prediction of defervescence and hospitalization length 2. To examine the kinetics of procalcitonin in pediatric patients with bacterial infections and persistent fever

NCT ID: NCT00690378 Completed - Clinical trials for Complicated Urinary Tract Infection

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.

NCT ID: NCT00678028 Completed - Clinical trials for Recurrent Urinary Tract Infections

Association Between Deficiency of MBL (Mannose-Binding Lectin) and Polymorphisms in MBL2 Gene to Urinary Tract Infection

Start date: February 2008
Phase: N/A
Study type: Observational

Due to genetic polymorphism about 15%-30% of the world population have low levels of MBL (Mannose Binding Lectin) in serum (below 500ng/mL). Different studies reported correlation between polymorphism in the MBL gene with low levels of MBL in serum and higher frequency of recurrent infections, severity of sepsis, ARDS and other infections. Urinary Tract Infection (UTI) is one of the very common infection in women. Since MBL is part of the innate immunity and there are proofs of relation between patients with recurrent infections and lack of MBL, we decided to explore a possible relation between low levels of MBL and different genotypes of MBL in young women and the risk to develop recurrent UTI.

NCT ID: NCT00676533 Completed - Clinical trials for Urinary Tract Infection

Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

Start date: June 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once daily for 3 days.

NCT ID: NCT00672503 Completed - Clinical trials for Urinary Tract Infections

Decreasing Catheter-Associated Urinary Tract Infections in the Pediatric Intensive Care Unit

Start date: May 2008
Phase: N/A
Study type: Observational

The purpose of this study is to identify risk factors associated with indwelling urinary catheters, as well as to assess the nurses' knowledge and adherence to hospital policies. The study will also include a very extensive literature search in an attempt to create a national standard or guideline.

NCT ID: NCT00669994 Completed - Clinical trials for Urinary Tract Infection

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

Start date: July 2003
Phase: Phase 4
Study type: Interventional

This trial evaluated how effective and safe Cipro XR was in treating female patients with signs and symptoms of a lower urinary tract infections. After 3 days of treatment, patients were evaluated to determine if signs/symptoms disappeared and the infecting bacteria was eliminated.